Reliable genotypic tropism tests for the major HIV-1 subtypes

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Cashin, Kieran ^a,b   Gray, Lachlan R ^a,c   Harvey, Katherine L ^a,b   Perez Bercoff, Danielle ^d   Lee, Guinevere Q ^e   Sterjovski, Jasminka ^a,c   Roche, Michael ^a,c   Demarest, James F ^f   Drummond, Fraser ^f   Harrigan, P Richard ^e   Churchill, Melissa J ^a,c   Gorry, Paul R ^a,b,c,g  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^e HIV/AIDS   (Canada)

^f VIIV HEALTHCARE   (United States)

^g RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305-321); MARAVIROC; PEPTIDE FRAGMENT; TRIAZOLE DERIVATIVE;

ALGORITHM; AMINO ACID SEQUENCE; BIOLOGY; CHEMISTRY; GENETICS; GENOTYPE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MUTATION; PHENOTYPE; PHYSIOLOGY; VIRAL TROPISM;

ALGORITHMS; AMINO ACID SEQUENCE; CCR5 RECEPTOR ANTAGONISTS; COMPUTATIONAL BIOLOGY; CYCLOHEXANES; GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS; PHENOTYPE; RECEPTORS, CCR5; TRIAZOLES; VIRAL TROPISM;

EID: 84923886473     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08543     Document Type: Article

References (76)

1. Joint United Nations Programme on HIV/AIDS report on the global AIDS epidemic. UNAIDS 1, 1-198 (2013).
2. Dorr, P. et al.Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49, 4721-4732 (2005).
3. Cashin, K. et al. Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection. Retrovirology 10, 98 (2013).
4. Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S. & Landau, N. R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185, 621-628 (1997).
5. Connell, B. J. et al. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 22, 896-899 (2008).
6. Michler, K. et al. Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res Hum Retroviruses 24, 743-751 (2008).
7. Gulick, R. M. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359, 1429-1441 (2008).
8. Vandekerckhove, L., Verhofstede, C. & Vogelaers, D. Maraviroc: integration of a new antiretroviral drug class into clinical practice. J Antimicrob Chemother 61, 1187-1190 (2008).
9. Whitcomb, J. M. et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51, 566-575 (2007).
10. Wilkin, T. J. et al. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 52, 925-928 (2011).
11. Raymond, S. et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 47, 126-130 (2010).
12. Braun, P. & Wiesmann, F. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. Eur J Med Res 12, 463-472 (2007).
13. Mulinge, M. et al. HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRRF01-AE and CRF02-AG. PloS one 8, e60566 (2013).
14. Lee, G. Q. et al. Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes. AIDS Res Hum Retroviruses 29, 979-984 (2013).
15. Lengauer, T., Sander, O., Sierra, S., Thielen, A. & Kaiser, R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 25, 1407-1410 (2007).
16. Swenson, L. C. et al. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. Clin Infect Dis 56, 1659-1666 (2013).
17. Swenson, L. C. et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 203, 237-245 (2011).
18. Swenson, L. C. et al. Deep V3 sequencing for HIV type 1 tropism in treatmentnaive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 53, 732-742 (2011).
19. Diez-Fuertes, F. et al. Improvement of HIV-1 coreceptor tropism prediction by employing selected nucleotide positions of the env gene in a Bayesian network classifier. J Antimicrob Chemother 68, 1471-1485 (2013).
20. Pillai, S., Good, B., Richman, D. & Corbeil, J. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 19, 145-149 (2003).
21. Cashin, K. et al. CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm. Retrovirology 10, 24 (2013).
22. Raymond, S. et al. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 47, 2292-2294 (2009).
23. Raymond, S. et al. Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 8, 56 (2011).
24. Jakobsen,M. R., Ellett, A., Churchill, M. J.& Gorry, P. R. Viral tropism, fitness and pathogenicity of HIV-1 subtype C. Future Virology 5, 219-231 (2010).
25. Hemelaar, J., Gouws, E., Ghys, P. D. & Osmanov, S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20, W13-23 (2006).
26. Hemelaar, J., Gouws, E., Ghys, P. D. & Osmanov, S. Isolation W-UNfH, Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25, 679-689 (2011).
27. Ng, K. Y. et al. High prevalence of CXCR4 usage among treatment-naive CRF01-AE and CRF51-01B-infected HIV-1 subjects in Singapore. BMC Infect Dis 13, 90 (2013).
28. Kato, S. et al. Differential prevalence of HIV type 1 subtype B and CRF01-AE among different sexual transmission groups in Tokyo, Japan, as revealed by subtype-specific PCR. AIDS Res Hum Retroviruses 19, 1057-1063 (2003).
29. De Jong, J. J., De Ronde, A., Keulen, W., Tersmette, M. & Goudsmit, J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66, 6777-6780 (1992).
30. Shioda, T., Levy, J. A. & Cheng-Mayer, C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci US A 89, 9434-9438 (1992).
31. Jensen, M. A., Coetzer,M., van 't Wout, A. B., Morris, L. & Mullins, J. I. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 80, 4698-4704 (2006).
32. Jensen, M. A. et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77, 13376-13388 (2003).
33. Hanley, J. A. & McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29-36 (1982).
34. Ataher, Q. et al. The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. J Int AIDS Soc 15, 2 (2012).
35. Cooper, D. A. et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 201, 803-813 (2010).
36. Reeves, J. D., Coakley, D. E., Petropoulos, C. J. & Whitcomb, J. M. An Enhanced-Sensitivity TrofileTM HIV Coreceptor Tropism Assay for Selecting Patients for Therapy with Entry Inhibitors Targeting CCR5: A Review of Analytical and Clinical Studies. The Journal of Viral Entry 3 (2009).
37. Trinh, L. et al. Validation of an enhanced sensitivity TrofileTM HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Journal of the International AIDS Society 11, 197 (2008).
38. Jakobsen, M. R. et al. Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naive Subjects with Progressive HIV-1 Subtype C Infection. PLoS One 8, e65950 (2013).
39. Raymond, S. et al. Genotypic prediction of HIV-1 CRF01-AE tropism. J Clin Microbiol 51, 564-570 (2013).
40. Hoffman, N. G., Seillier-Moiseiwitsch, F., Ahn, J., Walker, J. M. & Swanstrom, R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 76, 3852-3864 (2002).
41. Hwang, S. S., Boyle, T. J., Lyerly, H. K. & Cullen, B. R. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253, 71-74 (1991).
42. Schuitemaker, H., van 't Wout, A. B. & Lusso, P. Clinical significance of HIV-1 coreceptor usage. J Transl Med 9 Suppl 1, S5 (2011).
43. Raymond, S. et al. Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr 53, 167-175 (2010).
44. Dimonte, S. et al. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage. Virus Res 168, 73-83 (2012).
45. Dina, J. et al. Algorithm-based prediction of HIV-1 subtype D coreceptor use. J Clin Microbiol 51, 3087-3089 (2013).
46. Garrido, C. et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 46, 887-891 (2008).
47. Recordon-Pinson, P. et al. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 54, 3335-3340 (2010).
48. McGovern, R. A. et al. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr 61, 279-286 (2012).
49. Saag, M. et al. A double-blind, placebo-controlled trial ofmaraviroc in treatmentexperienced patients infected with non-R5 HIV-1. J Infect Dis 199, 1638-1647 (2009).
50. Kumar, R. & Raghava, G. P. Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence. PLoS One 8, e61437 (2013).
51. McGovern, R. A. et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24, 2517-2525 (2010).
52. Fatkenheuer, G. et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359, 1442-1455 (2008).
53. Kagan, R. M. et al. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatmentexperienced patients. PLoS One 7, e46334 (2012).
54. Gutierrez,C. et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 6, e27864 (2011).
55. Neff, C. P., Ndolo, T., Tandon, A., Habu, Y. & Akkina, R. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 5, e15257 (2010).
56. Ratner, L. et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-284 (1985).
57. Boisvert, S., Marchand, M., Laviolette, F. & Corbeil, J. HIV-1 coreceptor usage prediction without multiple alignments: an application of string kernels. Retrovirology 5, 110 (2008).
58. Fouchier, R. A. et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66, 3183-3187 (1992).
59. Lin, N. H. et al. Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology 433, 296-307 (2012).
60. Esbjornsson, J. et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02-AG during late-stage disease-indication of an evolving epidemic in West Africa. Retrovirology 7, 23 (2010).
61. Cashin, K. et al. Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4 1 T-cell subsets, including stem cell memory T-cells. Retrovirology 11, 97 (2014).
62. Cashin, K. et al. Alternative coreceptor requirements for efficient CCR5-and CXCR4-mediated HIV-1 entry into macrophages. J Virol 85, 10699-10709 (2011).
63. Cashin, K. et al. Covariance of charged amino acids at positions 322 and 440 of HIV-1 Env contributes to coreceptor specificity of subtype B viruses, and can be used to improve the performance of V3 sequence-based coreceptor usage prediction algorithms. PLoS One 9, e109771 (2014).
64. Gorry, P. R. et al. Changes in theV3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology 362, 163-178 (2007).
65. Huang, W. et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 81, 7885-7893 (2007).
66. Laakso, M. M. et al. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS pathogens 3, e117 (2007).
67. Milich, L., Margolin, B. H. & Swanstrom, R. Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology 239, 108-118 (1997).
68. Nabatov, A. A. et al. Intrapatient alterations in the human immunodeficiency virus type 1 gp120V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 78, 524-530 (2004).
69. Neogi, U. et al. Genetic analysis of HIV-1 Circulating Recombinant Form 02-AG, B and C subtype-specific envelope sequences from Northern India and their predicted co-receptor usage. AIDS research and therapy 6, 28 (2009).
70. Norrgren, H., Bamba, S., Da Silva, Z. J., Koivula, T. & Andersson, S. Higher mortality in HIV-2/HTLV-1 co-infected patients with pulmonary tuberculosis in Guinea-Bissau, West Africa, compared to HIV-2-positive HTLV-1-negative patients. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 14 Suppl 3, e142-147 (2010).
71. Resch, W., Hoffman, N. & Swanstrom, R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288, 51-62 (2001).
72. Rosen, O., Samson, A. O. & Anglister, J. Correlated mutations at gp120 positions 322 and 440: implications for gp120 structure. Proteins 71, 1066-1070 (2008).
73. Rosen, O., Sharon,M., Quadt-Akabayov, S. R. & Anglister, J. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc Natl Acad Sci USA 103, 13950-13955 (2006).
74. Suphaphiphat, P., Essex, M. & Lee, T. H. Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor. Virology 360, 182-190 (2007).
75. Zhang, H. et al.Molecular determinants of HIV-1 subtype C coreceptor transition from R5 to R5X4. Virology 407, 68-79 (2010).
76. Ajoge, H. O. et al. Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02-AG isolates. PLoS One 6, e17865 (2011).